6-K 1 a9906h.htm HOLDING(S) IN COMPANY a9906h

 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2024
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
 
99.1
 22 March 2024 - “Holding(s) in Company”
 
 
 
 
 
99.1
 
22 March 2024
HALEON PLC 
​(“Haleon” or “the Company”)  
​ 
TR-1: Standard form for notification of major holdings ​ 
1. Issuer Details
 
ISIN
 
GB00BMX86B70
 
Issuer Name
 
HALEON PLC
 
UK or Non-UK Issuer
 
UK
 
2. Reason for Notification
 
An acquisition or disposal of voting rights
 
3. Details of person subject to the notification obligation
 
Name
 
Pfizer Inc.
 
City of registered office (if applicable)
 
New York
 
Country of registered office (if applicable)
 
United States of America
 
4. Details of the shareholder
 
Name
 
City of registered office
 
Country of registered office
 
Guaranty Nominees Limited
 
London
 
United Kingdom
 
BofA Securities, Inc.
 
Wilmington, Delaware
 
United States of America
 
 
5. Date on which the threshold was crossed or reached
 
21-Mar-2024
 
6. Date on which Issuer notified
 
21-Mar-2024
 
7. Total positions of person(s) subject to the notification obligation
 
.
 
% of voting rights attached to shares (total of 8.A)
 
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
 
Total of both in % (8.A + 8.B)
 
Total number of voting rights held in issuer
 
Resulting situation on the date on which threshold was crossed or reached
 
22.580000
 
0.000000
 
22.580000
 
2062236079
 
Position of previous notification (if applicable)
 
32.000000
 
0.000000
 
32.000000
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
8A. Voting rights attached to shares
 
Class/Type of shares ISIN code(if possible)
 
Number of direct voting rights (DTR5.1)
 
Number of indirect voting rights (DTR5.2.1)
 
% of direct voting rights (DTR5.1)
 
% of indirect voting rights (DTR5.2.1)
 
Ordinary Shares GB00BMX86B70
 
 
1667778175
 
 
18.260000
 
Restricted ADSs
 
 
394457904
 
 
4.320000
 
Sub Total 8.A
 
2062236079
 
22.580000%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
 
Expiration date
 
Exercise/conversion period
 
Number of voting rights that may be acquired if the instrument is exercised/converted
 
% of voting rights
 
 
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
 
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
 
 
Ultimate controlling person
 
Name of controlled undertaking
 
% of voting rights if it equals or is higher than the notifiable threshold
 
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
 
Total of both if it equals or is higher than the notifiable threshold
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
The number and % of voting rights held
 
 
 
The date until which the voting rights will be held
 
 
 
11. Additional Information
 
This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").
 
 
Pfizer sold 594,000,000 Haleon ordinary shares and 196,554,820 ordinary shares in the form of American depositary shares, each representing two ordinary shares ("ADSs") pursuant to a global offer. In connection with the global offer, Haleon repurchased 102,272,727 ordinary shares from Pfizer in accordance with the terms of a share purchase deed between Haleon and Pfizer dated 11 September 2023 and approved by Haleon’s shareholders at its annual general meeting on 20 April 2023.
These calculations are based on an issued share capital of Haleon of 9,132,301,104 ordinary shares, following cancellation of the 102,272,727 ordinary shares repurchased from Pfizer, as communicated by Haleon in their announcement on total voting rights and capital dated 21 March 2024.
 
Pfizer holds its ordinary shares in Haleon through (i) BofA Securities, Inc., and (ii) Guaranty Nominees Limited (in respect of the ADSs), which hold the legal title to those shares on Pfizer's behalf.
 
 
12. Date of Completion
 
21-Mar-2024
 
13. Place Of Completion
 
New York, USA
 
Amanda Mellor, Company Secretary
 
 
 
 
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: March 22, 2024
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary